Cardiff-based Antiverse, a biotechnology company developing AI-powered therapeutic antibody discovery tools, has closed a $9.3 million Series A financing to expand its computational platform and advance lead programmes toward in vivo studies. The round was led by Soulmates Ventures with participation from Innovation Investment Capital, DOMiNO Ventures, and existing backers including DBW, Kadmos Capital and […]

This story continues at The Next Web